title: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
abstract: CTL are a critical component of protective immunity against viral infections, but requirements for in vivo priming of CTL are not completely understood. Covalent linkage of a helper determinant to a CTL determinant, analogous to that required for cognate help for antibody production, does not appear to be necessary in vitro, but its necessity has not been extensively explored in vivo, especially at a molecular level. We previously defined peptides encompassing multideterminant regions of HIV-1 gp160 (cluster peptides) recognized by Th from mice and humans of multiple MHC types. To investigate the requirement for Th in the development of CTL in vivo, in the context of developing a synthetic peptide vaccine for HIV active in multiple strains of mice, we immunized with compound peptides representing an immunodominant CTL epitope, P18, of gp160, co-linearly synthesized at the C-terminus of three cluster peptides. Spleen cells from compound-peptide-immunized mice of three MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules exhibited enhanced gp160-specific CD8+ CTL activity and CD4+ Th. In contrast, immunization with P18 alone or a mixture of cluster peptide and P18 elicited only marginal CTL activity. These results imply a requirement for determinant linkage in CTL induction in vivo similar to that already well recognized for cognate help for antibody induction. The results also define promising peptide HIV vaccine candidates for induction of CTL, as well as neutralizing antibodies, in diverse MHC types.
authors.affiliation: Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: M
authors.initials: M
authors.lastname: Shirai
authors.forename: C D
authors.initials: CD
authors.lastname: Pendleton
authors.forename: J
authors.initials: J
authors.lastname: Ahlers
authors.forename: T
authors.initials: T
authors.lastname: Takeshita
authors.forename: M
authors.initials: M
authors.lastname: Newman
authors.forename: J A
authors.initials: JA
authors.lastname: Berzofsky
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D000818:Animals; D016827:CD8 Antigens / Q000276:immunology; D015686:Gene Products, env / Q000276:immunology; D006678:HIV / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D006239:Haplotypes; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007111:Immunity, Cellular; D008211:Lymphocyte Cooperation; D051379:Mice; D008969:Molecular Sequence Data; D010455:Peptides / Q000276:immunology; D011498:Protein Precursors / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D016827:CD8 Antigens; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D011498:Protein Precursors